---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-041807"
form_type: "8-K/A"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2026-09-08T21:29:33+00:00"
generated_at: "2026-09-08T21:30:08.297829+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vivos exchanges $2.86M Streeterville debt for 11.45M shares, 52% dilution

## Summary
- Exchanged $2,861,270 of Streeterville Note principal for 11,445,080 common shares (avg $0.25/share) on Sept 2, 2026.
- Shares represent ~52% of pre-exchange outstanding (22,164,313) and ~34% of post-exchange (33,609,393).
- Following exchanges, Streeterville Note balance reduced to $3.7 million; no cash proceeds received.
- Exchanges done via 12 agreements; shares unregistered, issued under Section 3(a)(9).
- Amendment corrects original 8-K report date to Sept 2, 2026; transactions consummated that date.

## SEC filing metadata
- accession: 0001493152-26-041807
- form_type: 8-K/A
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2026-09-08T21:29:33+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315226041807/0001493152-26-041807-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315226041807/form8-ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-041807
- JSON: https://secwatch.observer/filing/0001493152-26-041807.json
- Plain text: https://secwatch.observer/filing/0001493152-26-041807.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.